Background: Methicillin resistant S. aureus (MRSA) has been declining over the past
INTRODUCTION
Staphylococcus aureus is one of the most common bacterial pathogens 1, 2 . A commensal organism that colonizes the skin and nares of approximately 20% of the population persistently and 60% intermittently 3 , it causes a range of invasive diseases, including skin and soft tissue infection (SSI), bone and joint infection, pneumonia, and bacteremia.
Infections are often severe: in 2009, out of 40 million total hospitalizations, an estimated 700,000 were S. aureus-related, yielding a rate of 17.7 per 1,000 hospitalizations 4 .
Much effort has focused on characterizing the emergence and spread of antibiotic resistant S. aureus lineages 5 . Resistance to penicillin was documented soon after its introduction and is mediated by a plasmid-borne b-lactamase encoded by the blaZ gene 6 . The penicillin resistant phage type 80/81 clone was highly prevalent in the 1950s, before mostly disappearing with the introduction of methicillin in 1960. Subsequently, methicillin resistant S. aureus (MRSA) emerged, with resistance conferred by the staphylococcal chromosome cassette mec (SCCmec), a genetic element that contains the methicillin resistance gene mecA. An "archaic" MRSA clone was prevalent until the 1970s and was superseded by the emergence of hospital-associated (HA-MRSA) lineages in the mid to late 1970s, and community-associated (CA-MRSA) lineages in the mid to late 1990s. In the United States the most widesread hospital-associated clonal complex is CC5, which contains the multi-drug resistant MRSA strain known as USA100.
Infections acquired in the community are often due to the MRSA strain USA300, which belongs to CC8 7 , though there is evidence for transmission of this lineage in the hospital setting 8 .
The high prevalence of MRSA infections 9, 10 and the increased mortality, cost, and length of hospital stay of individuals infected with MRSA as compared to methicillin susceptible S. aureus (MSSA) 11, 12 focused research on describing MRSA epidemiology. In the US and Europe, MRSA incidence peaked in 2005 and has been declining steadily since then 10, [13] [14] [15] [16] [17] . While the factors driving the decline in MRSA infections are not fully known, infection control efforts in healthcare facilities appear to have reduced the rates of transmission and infection in colonized individuals [16] [17] [18] . Evidence from the UK suggests that intrinsic fitness differences between clonal complexes have resulted in a lineage specific decline, possibly due to alterations in selective pressures from changing antimicrobial use 15, 16, [19] [20] [21] [22] .
In contrast with the extensive efforts to characterize MRSA, only a small number of studies have characterized the dynamics of all S. aureus subtypes, possibly due to the expectation that prevalence of penicillin susceptible S. aureus (PSSA) is extremely low 23 . However, recent reports from diverse sites describe a rising or surprisingly high prevalence of PSSA [24] [25] [26] [27] . Whether this trend is associated with the decline in MRSA and how it impacts overall rates of S. aureus infection are unclear. Furthermore, recent
analyses of large datasets of S. aureus genome sequences have provided evidence that resistance is not permanent, but can be acquired and shed 28, 29 . However, whether this is generalizable to S. aureus lineages present in the United States is unclear.
To determine the overall dynamics of antibiotic resistance in S. aureus and evaluate the hypothesis that the decline in rates of MRSA infection has been accompanied by both an absolute and relative increase in PSSA incidence, we analyzed electronic records of S.
aureus infections in hospitalized patients from 2000 to 2014 at two tertiary care hospitals in Boston, MA. Through whole genome sequencing of contemporary S. aureus invasive isolates, we tested the extent to which the trends are associated with specific S. aureus lineages and used phylogenomic methods to quantify the gains and losses of penicillin and methicillin resistance.
METHODS

Clinical data
Clinical and microbiology information was collected for all inpatients admitted to the 30 , and the site of infection. Surveillance swabs were excluded. To account for multiple specimens obtained from the same individual, we included the first clinical specimen and excluded specimens with identical antibiograms from the individual collected in the subsequent 2 weeks. We generated two additional datasets using 4 and 6 weeks as the cutoff. Specimens were categorized into four sites of infection: blood, lung (sputum and bronchoscopy specimens), skin and soft tissue (SSI), and other (bone / joint specimens, tissue biopsies, specimens collected from a visceral compartment, urine, and miscellaneous).
Clinical microbiology
Clinical specimens were analyzed for susceptibility to penicillin (P), methicillin (M),
trimethoprim-sulfamethoxazole (TMP-SMX), rifampin and vancomycin. We define antibiogram-type by the set of antibiotics to which the specimen is resistant. For example, 'PME' signifies resistance to penicillin, methicillin, and erythromycin. See Figure S1 of the supplement for the timeline of testing protocols. Susceptibility breakpoints were per Clinical and Laboratory Standards Institute (CLSI) guidelines over the study period; isolates that were 'intermediate' by CLSI breakpoints were grouped with resistant isolates for all analyses. We included data for susceptibility to clindamycin after 2010 only since this was the first full year both hospitals performed inducible clindamycin resistance testing on all specimens automatically through the Vitek machine. We categorized a specimen as PSSA if it was susceptible to penicillin and methicillin, MSSA if it was resistant to penicillin but susceptible to methicillin, and MRSA if it was resistant to both penicillin and methicillin.
Statistical analyses
We analyzed the rate of infection by S. aureus per 1,000 inpatient admissions and the mean number of antibiotics to which specimens are resistant. Annual percent changes in counts were adjusted for patient volume. Prospective specimen collection, sequencing, and analysis
We collected non-duplicate clinical specimens from patients ≥18 years of age who had specimens submitted to the BWH clinical microbiology laboratory between January 1, a microfluidic platform using the Illumina Nextera protocol as described 32 Clonal complex, multilocus sequence types, and SCCmec types were assigned using eBURST 37 and online databases 38, 39 . We constructed a maximum likelihood phylogeny from the reference-based SNPs using RAxML 40 and ST152 (GenBank NZ_LN854556.1)
as the outgroup. We inferred by parsimony the number of acquisitions and losses of SCCmec within ST5 and ST8 using Mesquite 41 , using N315 (GenBank NC_002745.2) as the reference genome for ST5 and USA300 (GenBank NC_010079.1) as the reference genome for ST8 isolates and with removal of Gubbins-predicted recombination blocks 42 .
All genome sequences have been deposited in the National Center for Biotechnology Information Sequence Read Archive (SRA) under SRA accession no. PRJNA380282.
RESULTS
Clinical and microbiologic characteristics of S. aureus
Our dataset comprised records of 43,954 S. aureus infections, including 21,779 MRSA, 17,565 MSSA, and 4,610 PSSA (Table 1) . Patients with MRSA infection were older, had more comorbidities, and more often had lung as the site of infection compared to patients with MSSA or PSSA. Patients with PSSA were older and had more comorbidities compared to those with MSSA but were similar in terms of site of infection.
Seventy-eight percent of all specimens belonged to five antibiogram-types ( infections per 1,000 inpatients MSSA declined by 2.2% annually (95% CI 0.4%-4.0%) from 11.7 to 9.2 infections per 1,000 inpatients. There was no change in trends when using 4 and 6 week duplicate exclusion criteria ( Figure S2 of the supplement).
Rates of infection for the drug-resistant antibiogram-type PMEL declined annually by 11.3% (95% CI 9.2%-13.3%), while rates for the PME antibiogram-type increased annually by 6.6% (95% CI 2.1%-11.3%; figure 1B and table 2 ). For the two major MSSA antibiogram-types (PE and P), rates did not change significantly over this time period.
The pan-susceptible antibiogram-type increased by 4.5% annually (95% CI 2.3%-6.8%).
The rates for the PME and pan-susceptible antibiogram-types did not significantly differ.
In the analysis including clindamycin for the interval 2010 to 2014, we observed a significant decline in the PMECL antibiogram-type (6.9%, 95% CI 3.7%-10.2%) and a significant increase in the P (3.3%, 95% CI 0.0%-6.6%) and pan-susceptible (10.5%, 95% CI 4.8-16.5%) antibiogram-types ( Figure S3 of the supplement).
One explanation for the decline in the MRSA PMEL antibiogram-type is decreasing exposure to antibiotics, particularly fluoroquinolones. We evaluated the rates of resistance to erythromycin, clindamycin and levofloxacin and observed a significant decline for all three drugs in MRSA, a decline for levofloxacin and erythromycin in PSSA, and a decline in erythromycin resistance in MSSA ( Figure S4 of the supplement).
Changes in mean antibiotic resistance
Given the rise in PSSA and the decline in multidrug resistant S. aureus, we tested whether overall susceptibility of S. aureus changed during the study period. In 2000, a S.
aureus infection was on average resistant to 3. (Table S2 of the supplement). Of PMEL isolates, 97% were CC5 and 94% of these were also resistant to clindamycin (PMECL). Of PME isolates, 80% were CC8 and only 20% of these were resistant to clindamycin (Tables S3 and S4 of the supplement). The distribution of gender, comorbidities, race and site of infection differed due to small sample size in the PME group, but otherwise the clinical characteristics of these antibiogram-types were similar between the prospective and retrospective samples (Table S5 of The observed decline in the rate of MRSA infection does not reflect a decline in all MRSA strains. As the declining MRSA PMECL antibiogram-type is mostly hospitalassociated CC5 and the increasing MRSA PME antibiogram-type is mostly the community-associated CC8, we note that the decline of MRSA appears to be occurring predominantly in strains adapted to the health care setting. The demographic and clinical characteristics of patients with infection from PME isolates support this hypothesis, as they are younger, healthier, and more likely to present with skin and soft tissue infections.
As shown here, studies of MRSA incidence alone fail to capture the dynamics of the overall S. aureus population. The observation that penicillin and methicillin resistance are gained and lost at the strain level represents a departure from the dogma that population level resistance is driven by the transmission of lineages with stable resistance phenotypes. Similar findings were noted in a recent study from France that showed in vivo loss of methicillin resistance in CC30, a common European lineage that has been on the decline since 2005 29 .
One potential explanation for the loss of resistance across multiple lineages is shifting antibiotic pressures. The decline in use of narrow spectrum beta-lactams such as oxacillin and penicillin G since 2000 [43] [44] [45] [46] and in the inpatient use of first generation cephalosporins since 2006 44 may select against HA-MRSA and in favor of PSSA, but does not on its own explain the rise in CA-MRSA. We also note a decline in levofloxacin resistance in MRSA and PSSA over a time period when use of levofloxacin declined significantly inpatient settings 44 . This suggests that fitness costs associated with fluoroquinolone resistance in S. aureus may be a factor in the decline in HA-MRSA and the increase in CA-MRSA and PSSA, which are largely quinolone susceptible. In contrast, use of TMP-SMX increased nationally over the time period of our study 44, 47, 48 but TMP-SMX resistance remained <5%. This raises the question whether the fitness cost incurred by TMP-SMX resistance is higher than those incurred by fluoroquinolone resistance.
There are several limitations to our study. First, testing for inducible beta-lactamase production was not routinely performed prior to 2011, raising the possibility that specimens reported as penicillin susceptible from this time period were in fact penicillin resistant. However, such a bias would augment the observed increases in rates of PSSA infection. Second, in the absence of genotyping of historical specimens, the evidence that the decline in MRSA has occurred disproportionately within CC5 relies on the consistency in the demographic and microbiologic characteristics of antibiogram-types between our retrospective and prospective cohorts. However, the over-representation of PMECL isolates in CC5 and PME isolates in CC8 suggests that these antibiogram-types may be rough proxies for lineage. Lastly, the generalizability of our results may be limited as the analysis is from 2 hospitals in the same geographic area. However, as the rate of decline of MRSA in our study is similar to the rate observed in a nationally representative study 13 and recent reports from geographically diverse institutions note increased rates of PSSA infection, these trends may be widespread. A major strength of this study was the unbiased analysis of the overall S. aureus population, whereas most prior studies have examined only the MRSA subpopulation. This has yielded a more complete picture of the clonal dynamics of this highly adaptable pathogen.
The decline in antibiotic resistance in S. aureus over the past 10 years runs counter to the prevailing paradigm of an inexorable rise of multidrug resistance among human pathogens. Defining the forces driving the decline will be a critical task to guide efforts to control S. aureus infection and antibiotic resistance. Further, as most clinical laboratories do not test for penicillin susceptibility, the increasing incidence of PSSA should prompt evaluation of broader geographic trends along with reevaluation of the cost-effectiveness of penicillin testing and treatment. 
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